tirzepatide 2.5 (Mounjaro) leads to substantial weight loss in diabetes patients Tirzepatide Injection, 2.5 Mg at

The temporary DEA extensions simply maintain flexibility for controlled substance prescribing while regulators work on permanent rules

Mojsovs role is especially relevant to this story

Highlights of Prescribing Information - Ozempic (semaglutide) Injection

Semaglutide is a GLP-1 receptor agonist that was originally formulated to treat diabetes by modulating blood sugar levels

This work was supported by the National Institute on Drug Abuse Intramural Research Program (M.F., G.R.M., M.N.N., V.M., O.A.A., M.A.H., and L.L.) and the National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research (M.F., G.R.M., V.M., and L.L.)

Even patients who have previously faced challenges losing weight have seen real, sustainable results with Tirzepatide